{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:01:08Z","timestamp":1780351268749,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81820108005"],"award-info":[{"award-number":["81820108005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270551"],"award-info":[{"award-number":["82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173241"],"award-info":[{"award-number":["82173241"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900502"],"award-info":[{"award-number":["81900502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2021ZDLSF02-07"],"award-info":[{"award-number":["2021ZDLSF02-07"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2023ZDLSF-33"],"award-info":[{"award-number":["2023ZDLSF-33"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Program of Shaanxi","doi-asserted-by":"crossref","award":["2023KJXX-026"],"award-info":[{"award-number":["2023KJXX-026"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Plan Project of Shaanxi","award":["2024RS-CXTD-79"],"award-info":[{"award-number":["2024RS-CXTD-79"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Some patients treated with ursodeoxycholic acid (UDCA) or combined fenofibrate had well-controlled biochemical parameters but high liver stiffness, and the prognosis as well as therapeutic options for these patients may be an area worthy of further exploration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>To explore the prognosis and treatment of patients with low-risk and high liver stiffness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective study included 424 cases of UDCA monotherapy and 102 cases of combined fenofibrate treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The combination of liver stiffness measurement (LSM) and the GLOBE score improved prognostic prediction for patients with UDCA monotherapy (area under the receiver operating characteristic curve [AUC] of 0.868 (0.811\u20130.925) for the fitted model and 0.834 (0.767\u20130.900) for the GLOBE score, <jats:italic>p<\/jats:italic>\u2009=\u20090.006). Further analyses revealed that LSM had an additive prognostic effect mainly in low-risk patients defined by GLOBE\u2009&lt;\u20090.5 (AUC, 0.777 [0.724\u20130.825] vs 0.642 [0.583\u20130.699], <jats:italic>p<\/jats:italic>\u2009=\u20090.001). For patients in the low-risk group, the prognosis was worse when LSM\u2009&gt;\u200911\u00a0kPa (7\/53 [13%] vs 2\/227 [1%], <jats:italic>p<\/jats:italic>\u2009=\u20090.001). The prognosis was consistent between patients in the \u201clow-risk and LSM\u2009&gt;\u200911\u00a0kPa\u201d group and the medium-risk group defined by 0.5\u2009&lt;\u2009GLOBE\u2009&lt;\u20091.8 (7\/53 [13%] vs 22\/121 [18%], <jats:italic>p<\/jats:italic>\u2009=\u20090.418). In low-risk patients treated with combined fenofibrate therapy, the prognosis was worse when LSM\u2009&gt;\u200911\u00a0kPa (3\/21 [14%] vs 0\/47 [0%], <jats:italic>p<\/jats:italic>\u2009=\u20090.022). The prognosis was consistent between patients in the \u201clow-risk and LSM\u2009&gt;\u200911\u00a0kPa\u201d and the medium-risk groups (3\/21 [14%] vs 6\/27 [22%], <jats:italic>p<\/jats:italic>\u2009=\u20090.353). Antifibrotic drugs failed to reduce the incidence of the primary outcome (5\/45 [11%] vs 5\/27 [19%], <jats:italic>p<\/jats:italic>\u2009=\u20090.598), and delayed the progression of LSM in patients with low-risk and LSM\u2009&gt;\u200911\u00a0kPa at 36\u00a0months of follow-up (changes in LSM, \u2212\u20093.31 [\u2212\u20095.04 to \u2212\u20091.52] vs \u2212\u20091.74 [\u2212\u20092.83 to 1.5], <jats:italic>p<\/jats:italic>\u2009=\u20090.046).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients with GLOBE-defined low-risk and LSM\u2009&gt;\u200911\u00a0kPa had a poor prognosis, and antifibrotic therapy may slow the progression of liver stiffness in these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12072-024-10743-w","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T08:02:50Z","timestamp":1733904170000},"page":"673-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment"],"prefix":"10.1007","volume":"19","author":[{"given":"Dawei","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanya","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-9507","authenticated-orcid":false,"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"issue":"10266","key":"10743_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","volume":"396","author":"A Lleo","year":"2020","unstructured":"Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020;396(10266):1915\u20131926","journal-title":"Lancet"},{"issue":"1","key":"10743_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","volume":"16","author":"H You","year":"2022","unstructured":"You H, Ma X, Efe C, et al. Apasl clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022;16(1):1\u201323","journal-title":"Hepatol Int"},{"issue":"1","key":"10743_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C, et al. Easl clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u2013172","journal-title":"J Hepatol"},{"issue":"2","key":"10743_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357\u2013365","journal-title":"J Hepatol"},{"issue":"6","key":"10743_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361\u20131367","journal-title":"J Hepatol"},{"issue":"6","key":"10743_CR6","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338\u20131349","journal-title":"Gastroenterology"},{"issue":"4","key":"10743_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EMM Kuiper","year":"2009","unstructured":"Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281\u20131287","journal-title":"Gastroenterology"},{"issue":"10","key":"10743_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186\u20132194","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10743_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u2013877","journal-title":"Hepatology"},{"issue":"11\u201312","key":"10743_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/apt.12522","volume":"38","author":"V Papastergiou","year":"2013","unstructured":"Papastergiou V, Tsochatzis EA, Rodriquez Peralvarez M, et al. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther. 2013;38(11\u201312):1354\u20131364","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10743_CR11","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149(7):1804\u20131812","journal-title":"Gastroenterology"},{"issue":"7","key":"10743_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrgastro.2016.86","volume":"13","author":"M Friedrich-Rust","year":"2016","unstructured":"Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016;13(7):402\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10743_CR13","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/hep.31810","volume":"74","author":"L Cristoferi","year":"2021","unstructured":"Cristoferi L, Calvaruso V, Overi D, et al. Accuracy of transient elastography in assessing fibrosis at diagnosis in naive patients with primary biliary cholangitis: a dual cut-off approach. Hepatology. 2021;74(3):1496\u20131508","journal-title":"Hepatology"},{"issue":"1","key":"10743_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.25599","volume":"56","author":"C Corpechot","year":"2012","unstructured":"Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56(1):198\u2013208","journal-title":"Hepatology"},{"issue":"6","key":"10743_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","volume":"77","author":"C Corpechot","year":"2022","unstructured":"Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022;77(6):1545\u20131553","journal-title":"J Hepatol"},{"issue":"3","key":"10743_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","volume":"114","author":"C Moctezuma-Velazquez","year":"2019","unstructured":"Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S, et al. Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114(3):446\u2013452","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10743_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12072-023-10587-w","volume":"18","author":"D Ding","year":"2024","unstructured":"Ding D, Guo G, Cui L, et al. Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria. Hepatol Int. 2024;18(1):206\u2013215","journal-title":"Hepatol Int"},{"issue":"2","key":"10743_CR18","first-page":"304","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang C, Li J, et al. An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir. J Clin Transl Hepatol. 2022;11(2):304","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10743_CR19","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","volume":"77","author":"D Ji","year":"2022","unstructured":"Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022;77(6):1515\u20131524","journal-title":"J Hepatol"},{"issue":"19","key":"10743_CR20","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3748\/wjg.v11.i19.2892","volume":"11","author":"P Liu","year":"2005","unstructured":"Liu P, Hu YY, Liu C, et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol. 2005;11(19):2892\u20132899","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10743_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","volume":"165","author":"S Man","year":"2023","unstructured":"Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025\u20131040","journal-title":"Gastroenterology"},{"issue":"1","key":"10743_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.23637","volume":"52","author":"MG Silveira","year":"2010","unstructured":"Silveira MG, Brunt EM, Heathcote J, et al. American association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52(1):349\u2013359","journal-title":"Hepatology"},{"issue":"10","key":"10743_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/apt.15533","volume":"50","author":"CF Murillo Perez","year":"2019","unstructured":"Murillo Perez CF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50(10):1127\u20131136","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10743_CR24","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/hep4.2103","volume":"6","author":"D Ding","year":"2022","unstructured":"Ding D, Guo G, Liu Y, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol Commun. 2022;6(12):3487\u20133495","journal-title":"Hepatol Commun"},{"key":"10743_CR25","doi-asserted-by":"publisher","first-page":"948362","DOI":"10.3389\/fphar.2022.948362","volume":"13","author":"X Guoyun","year":"2022","unstructured":"Guoyun X, Dawei D, Ning L, et al. Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: a retrospective study and updated meta-analysis. Front Pharmacol. 2022;13:948362","journal-title":"Front Pharmacol"},{"key":"10743_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000826","volume":"80","author":"J Ampuero","year":"2024","unstructured":"Ampuero J, Lucena A, Berenguer M, et al. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy. Hepatology. 2024;80:791\u2013806","journal-title":"Hepatology"},{"issue":"6","key":"10743_CR27","first-page":"974","volume":"113","author":"L Wang","year":"2022","unstructured":"Wang L, Sun K, Tian A, et al. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. Minerva Med. 2022;113(6):974\u2013982","journal-title":"Minerva Med"},{"issue":"6","key":"10743_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/aps.2017.101","volume":"39","author":"Y Song","year":"2018","unstructured":"Song Y, Chen J, Cai F, et al. A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes. Acta Pharmacol Sin. 2018;39(6):942\u2013951","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10743_CR29","doi-asserted-by":"publisher","first-page":"18719","DOI":"10.1038\/s41598-019-54663-4","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu H, Lv J, Zhao Z, et al. Fuzhenghuayu decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. Sci Rep. 2019;9(1):18719","journal-title":"Sci Rep"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10743-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10743-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10743-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:29:23Z","timestamp":1749054563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10743-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10743"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10743-w","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dawei Ding, Yinan Hu, Gui Jia, Boling Wang, Linhua Zheng, Juan Deng, Ruiqing Sun, Xiufang Wang, Guanya Guo, Lina Cui, Yulong Shang and Ying Han have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}